RhumbLine Advisers’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $3.89M | Buy |
|
|||||
|
2025
Q2 | $2.74M | Buy |
|
|||||
|
2025
Q1 | $2.77M | Sell |
|
|||||
|
2024
Q4 | $2.32M | Sell |
|
|||||
|
2024
Q3 | $2.52M | Buy |
|
|||||
|
2024
Q2 | $2.69M | Buy |
|
|||||
|
2024
Q1 | $2.53M | Sell |
|
|||||
|
2023
Q4 | $2.09M | Sell |
|
|||||
|
2023
Q3 | $2.3M | Buy |
|
|||||
|
2023
Q2 | $1.88M | Buy |
|
|||||
|
2023
Q1 | $1.35M | Buy |
|
|||||
|
2022
Q4 | $1.27M | Buy |
|
|||||
|
2022
Q3 | $986K | Buy |
|
|||||
|
2022
Q2 | $896K | Buy |
|
|||||
|
2022
Q1 | $728K | Buy |
|
|||||
|
2021
Q4 | $1.14M | Sell |
|
|||||
|
2021
Q3 | $1.02M | Sell |
|
|||||
|
2021
Q2 | $1.21M | Sell |
|
|||||
|
2021
Q1 | $1.26M | Buy |
|
|||||
|
2020
Q4 | $978K | Buy |
|
|||||
|
2020
Q3 | $859K | Sell |
|
|||||
|
2020
Q2 | $1.03M | Buy |
|
|||||
|
2020
Q1 | $1.29M | Buy |
|
|||||
|
2019
Q4 | $1.91M | Buy |
|
|||||
|
2019
Q3 | $2.09M | Buy |
|
|||||
|
2019
Q2 | $2.18M | Buy |
|
|||||
|
2019
Q1 | $1.7M | Sell |
|
|||||
|
2018
Q4 | $1.1M | Buy |
|
|||||
|
2018
Q3 | $1.17M | Sell |
|
|||||
|
2018
Q2 | $1.46M | Buy |
|
|||||
|
2018
Q1 | $1.19M | Buy |
|
|||||
|
2017
Q4 | $1.27M | Buy |
|
|||||
|
2017
Q3 | $891K | Buy |
|
|||||
|
2017
Q2 | $748K | Sell |
|
|||||
|
2017
Q1 | $796K | Buy |
|
|||||
|
2016
Q4 | $749K | Buy |
|
|||||
|
2016
Q3 | $734K | Buy |
|
|||||
|
2016
Q2 | $563K | Buy |
|
|||||
|
2016
Q1 | $333K | Buy |
|
|||||
|
2015
Q4 | $442K | Buy |
|
|||||
|
2015
Q3 | $360K | Buy |
|
|||||
|
2015
Q2 | $553K | Buy |
|
|||||
|
2015
Q1 | $557K | Buy |
|
|||||
|
2014
Q4 | $378K | Buy |
|